Abstract
One of the more consistent findings observed in post mortem tissue from schizophrenia (SZ) patients is that the genes encoding reelin and glutamate decarboxylase 67 (GAD67 or GAD1) are downregulated in cortex and other brain regions. Reelin is important for cortical migration during development and for synaptic plasticity and memory acquisition in the adult. GAD1 is one of two enzymes that synthesize the inhibitory neurotransmitter GABA in the central nervous system. Those neurons that make GABA are GABAergic and they serve a role in dampening excitatory neurotransmission throughout the brain. In addition, reports also show that NMDA receptor subunit expression and excitatory neurotransmission are reduced in cortical GABA neurons of SZ patients. Conditional knockout mice in which the NR1 subunit of the NMDA receptor is selectively reduced in GABA neurons of the brain show a downregulation of GAD67 and parvalbumin (PV) mRNAs and also exhibit behaviors characteristic of SZ. These findings allow us to conceptually integrate two major schools of thought regarding the neurotransmitter deficit responsible for the symptoms of this psychiatric disorder. That is, if reduced glutamatergic neurotransmission occurs on GABAergic interneurons, the net effect would be reduced GABA output impacting the neuronal synchronization of pyramidal cell firing. Since it has also been shown that in GABAergic neurons, the mRNA encoding DNA methyltransferase 1 (DNMT1) is increased in SZ patients, this and other data suggest an epigenetic mechanism by which certain genes may be selectively downregulated contributing to SZ symptomatology. We propose that enzymes that methylate DNA and selectively reduce gene expression are hyperactive in patients with SZ and that this may be related to the pathogenesis of the disease. Here, we discuss these concepts in more detail and present our integrated view of synaptic transmission in SZ.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdolmaleky HMK, Cheng A, Russo CL, Smith SV, Faraon M, Wilcox R, Shafa SJ, Glatt G, Nguyen JF, Ponte S, Thiagalingam TMT (2005) Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 134:60–66
Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jones EG (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258–266
Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Quinlan Li Y, Nakazawa EMK (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13:76–83
Benes J, Vincent SL, Alsterberger G, Bird ED, San Giovanni JP (1992) Increased GABAergic receptor binding in superficial layers of cingulate cortex in schizophrenia. J Neurosci 12:924–929
Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M (2007) Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci USA 104:10164–10169
Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23:351–364
Broide RS, Redwine JM, Aftahi N, Yound W, Bloom FE, Winrow CJ (2007) Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci 31:47–58
Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR (2002) On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 30:2930–2939
Conn PJ, Lindsley CW, Jones CK (2008) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30:25–31
Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C (2001) Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 8:723–742
Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L, Veldic M (2004) A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 16:1–23
Costa E, Dong E, Grayson DR, Ruzicka WB, Simonini MV, Veldic M, Guidotti A (2006) Epigenetic targets in GABAergic neurons to treat schizophrenia. Adv Pharmacol 54:95–117
Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka WB, Veldic M (2007) Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2:29–36
D’Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T (1995) A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 376:292–293
Fatemi SH, Earle JA, McMenomy T (2000) Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 5:654–663
Gonzalez-Burgos G, Lewis DA (2008) GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34:944–961
Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12:904–922
Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, Guidotti A, Costa E (2005) Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 102:9341–9346
Grayson DR, Kundakovic M, Sharma RP (2010) Is there a future for HDAC inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77(2):126–135
Guidotti A, Auta J, Davis JM, Dwivedi Y, Gerevini VD, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov DP, Costa E (2000) Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder, a postmortem brain study. Arch Gen Psychiatry 57:1061–1069
Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E (2005) GABAergic dysfunction in schizophrenia: a new treatment on the horizon. Psychopharmacology (Berl) 180:191–205
Guidotti A, Ruzicka W, Grayson DR, Veldic M, Davis J, Costa E (2007) S-Adenosyl methionine and DNA-methyltransferase-1 overexpression in psychosis. Neuroreport 18:57–60
Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics K, Lewis DA (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13:147–161
Hayes SG (1989) Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 50:35S–39S
Hayman S (2008) A glimmer of light for neuropsychiatric disorders. Nature 455:890–893
Hooker JM, Kim SW, Alexoff D, Xu Y, Shea C, Reid A, Volkow N, Fowler JS (2010) Histone deactylase inhibitor MS-275 exhibits poor brain penetration: pharmakokinetic studies of [11C]MS-275 using positron emission tomography. ACS Chem Neurosci 1:65–73
Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496–11500
Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35:549–562
Impagnatiello F, Guidotti A, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E (1998) A decrease of reelin expression as a putative vulernability factor in schizophrenia. Proc Natl Acad Sci USA 95:15718–15723
Kundakovic M, Chen Y, Costa E, Grayson DR (2007) DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 71:644–653
Kundakovic M, Chen Y, Guidotti A, Grayson DR (2009) The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 75:342–354
Levenson JM, Qiu S, Weeber EJ (2008) The role of reelin in adult synaptic function and the genetic and epigenetic regulation of the reelin gene. Biochim Biophys Acta 1779:433–431
Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324
Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs, comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358–403
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234–242
Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S (2009) Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 65:1006–1014
Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A (2008) Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 82:696–711
Noh JS, Sharma RP, Veldic M, Salvacion AA, Jia X, Chen Y, Costa E, Guidotti A, Grayson DR (2005) DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci USA 102:1749–1754
Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, Szyf M, Anisman H (2008) GABAA receptor promoter hypermethylation in suicide brain, implications for the involvement of epigenetic processes. Biol Psychiatry 64:645–652
Ptak C, Petronis A (2008) Epigenetics and complex disease: from etiology to new therapeutics. Annu Rev Toxicol 48:257–276
Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A (2007) Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol Psychiatry 12:385–397
Satta R, Maloku E, Zhubi A, Pibiri F, Hajos M, Costa E, Guidotti A (2008) Subcutaneous nicotine decreases DNMT1 expression and GAD67 promoter methylation in selected populations of mouse telencephalic GABAergic neurons. Proc Natl Acad Sci USA 105:16356–16361
Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A (2006) The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 103:1587–1592
Soghomonian JJ, Martin DL (1998) Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci 19:500–505
Szyf M, McGowan P, Meaney MJ (2008) The social environment and the epigenome. Environ Mol Mutagen 49:46–60
Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, Sharma RP, Grayson DR, Costa E, Guidotti A (2002) An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 99:17095–17100
Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E, Guidotti A (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 57:500–509
Van Emburgh BO, Robertson KD (2008) DNA methyltransferases and methyl CpG binding proteins as multifunctional regulators of chromatin structure and development in mammalian cells. In: Tost J (ed) Epigenetics, Kaister. Academic, Norwich, UK, pp 23–62
Veldic M, Caruncho HJ, Liu WS, Davis J, Satta R, Grayson DR, Guidotti A, Costa E (2004) DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci USA 101:348–353
Veldic M, Guidotti A, Maloku E, Davis JM, Costa E (2005) In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 102:2152–2157
Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM, Costa E (2007) Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res 91:51–61
Woo TUW, Walsh JP, Benes FP (2005) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-d-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61:649–657
Woo TUW, Kim AM, Viscidi E (2008) Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res 1218:267–277
Wyatt RJ, Termini BA, Davis JM (1971) Biochemical and sleep studies of schizophrenia. A review of the literature 1960–1970. Schizophr Res 4:10–44
Zhubi A, Veldic M, Puri NV, Kadriu B, Caruncho H, Loza I, Sershen H, Lajtha A, Smith RC, Guidotti A, Davis JM, Costa E (2009) An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 111:115–122
Acknowledgments
We would like to dedicate this work to the memory of our friend and colleague, Dr. Erminio Costa, University of Illinois at Chicago, who died November 28, 2009.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grayson, D.R., Kundakovic, M., Chen, Y., Dong, E., Guidotti, A. (2011). Epigenetic Regulation of GABAergic Targets in Psychiatry. In: Petronis, A., Mill, J. (eds) Brain, Behavior and Epigenetics. Epigenetics and Human Health. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17426-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-17426-1_2
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17425-4
Online ISBN: 978-3-642-17426-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)